In this episode of Peptides Explained, John Garrett, RN, breaks down: What AOD-9604 is and how it differs from full-length HGH Lipolysis, lipogenesis, and beta-3 adrenergic signaling Why animal studies looked promising What the early human trials showed Why the obesity-development program was discontinued Whether AOD-9604 raises IGF-1 Regulatory status, risks, unknowns, and anti-doping concerns A responsible framework for evaluating experimental fat-loss peptides The central takeaway: AOD-9604 has a plausible preclinical mechanism, but the available human evidence does not establish dependable, clinically meaningful fat loss
GHK-Cu's Effectiveness Supported by Clinical and Scientific Evidence Various studies have proven the skin rejuvenation and anti-aging effects of GHK-Cu
Which Semaglutide Drugs Will Be Named In Lawsuits
FDA License Number CDRR-NCR-DS-573920
By integrating follow-up assessments into the program structure, MEDVi supports responsive care without reactive intervention
The pressure to bounce back can be relentless, and that pressure often gets internalized